Medicare Part D
-
340B, Affordable Care Act, Caught my eye, CMMI, Drug Prices, Healthcare Costs, ICER, Medicare Part D, Pharmacy Benefit Managers, Reference Pricing, State-based Reform, Utilization ManagementAMP is WAC — 12/19/25
Read more: AMP is WAC — 12/19/25Today we’re expecting to hear more about manufacturer Most Favored Nation (MFN) agreements and (if you trust the rumors) maybe more about the MFN demos – the Global Benchmark for Efficient Drug Pricing (GLOBE) Model and the Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model. I wasn’t planning on publishing the next two weeks,…
-
340B, Affordable Care Act, Caught my eye, CMMI, Drug Prices, Home Health, Inflation Reduction Act, Medicare Advantage, Medicare Negotiation, Medicare Part D, Preventative, Reference Pricing, TariffsAMP is WAC — 12/5/25
Read more: AMP is WAC — 12/5/25It is the kind of month where I walk around with a legal pad to capture all the random thoughts floating around my head. Which is how “figure out gift baking (scones? Levain cookies?)” ends up next to “Look at MedPAC agenda.” There are no dull moments around here. While I’m on the topic. MedPAC…
-
Affordable Care Act, Inflation Reduction Act, Medicare Advantage, Medicare Negotiation, Medicare Part D, Obesity, Utilization ManagementBack at it
Read more: Back at itHo, Ho. Ho, Ho. It’s likely back to work you go. If you checked out the last week, here is what you might need to know before you get too far into your week. I will have the regular AMP is WAC on Friday but a catch-up felt in order. Waiting Game. The rollout of…
-
340B, Affordable Care Act, CMMI, FDA, Inflation Reduction Act, Medicaid, Medicare Part D, State-based ReformAMP is WAC — 11/21/25
Read more: AMP is WAC — 11/21/25This week felt weirdly calm – I am sure I just jinxed it. No AMP is WAC next week. If something interesting happens, I’m sure I won’t be able to help myself and will post on LinkedIn. Have a great Thanksgiving and I hope you remember that nothing will change that person at the table,…
-
Affordable Care Act, Alzheimer’s, Biosimilars, Caught my eye, Drug shortages, FDA, Medicaid, Medicare Part D, UncategorizedAMP is WAC — 11/14/25
Read more: AMP is WAC — 11/14/25How is it mid-November? I think of all of the things that need to get done by the end of the year and then try and pull out the productivity schemes (5 choices, pomodoro, eat the frog, etc.) I’ve learned over the years. The problem is that none of these create more time, just make…
-
340B, Caught my eye, CMMI, Drug Prices, Medicaid, Medicare Negotiation, Medicare Part D, Obesity, Pharmacy Benefit ManagersAMP is WAC — 11/7/25
Read more: AMP is WAC — 11/7/25This week is such a kick in the pants with it getting dark so early. I’ve become like a cat chasing the daylight from room to room, ending my day on a swivel club chair that catches the very last rays of the setting sun. Have laptop, will travel. Shoe Drop. Late yesterday afternoon, the…
-
Biosimilars, Caught my eye, Generics, Health Equity, ICER, Medicare Advantage, Medicare Part D, Obesity, Pharmacy Benefit Managers, State-based Reform, Utilization Management, ValueAMP is WAC — 10/31/25
Read more: AMP is WAC — 10/31/25You won’t be surprised when I tell you that my favorite Halloween costume was when I wore a pair of scrubs with vinyl records attached (Spin Doctor). Yep. Right up there with Freudian slips. This year I will stick to my usual costume: the nice lady who hands out full-size bars to 200+ neighborhood kids.…
-
340B, Affordable Care Act, Caught my eye, Employers, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, ValueAMP is WAC — 10/24/25
Read more: AMP is WAC — 10/24/25This week, I felt like my brain experienced a “low memory” error. My capacity was maxed out trying to tackle a Python coding challenge—a task that exists in an entirely different universe than my usual work. It was a blend of excitement and absurdity. But being outside one’s comfort zone actually feels pretty relevant to…
-
CMMI, Drug Prices, Drug shortages, Generics, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Pharmacy Benefit Managers, State-based Reform, Supply ChainAMP is WAC — 10/17/25
Read more: AMP is WAC — 10/17/25Caught my Eye Cool Idea, But. The Food and Drug Administration (FDA) puts announced a new pilot prioritization program for the review of Abbreviated New Drug Applications (ANDAs) to support generic manufacturing in the U.S. I mean it sounds good, except… there are three criteria for applicants: Only 9% of API manufacturers are in the…
-
340B, Caught my eye, DTC, Medicaid, Medicare Negotiation, Medicare Part D, Reference Pricing, State-based ReformAMP is WAC — 10/10/25
Read more: AMP is WAC — 10/10/25Going crazy? Or is it just a party of one? This past month as been brutal. My house has been a parade of plumbers and HVAC and electricians. Plus, visits to orthopedists and veterinarians and car mechanics. If the universe is trying to say something, all I’m hearing is that I’m scoring a ton of…
Latest news
- AMP is WAC — 04/24/26
- AMP is WAC — 04/10/26
- AMP is WAC — 03/27/26
- AMP is WAC — 03/20/26
- AMP is WAC — 03/13/26
Categories
- 340B (64)
- Affordable Care Act (23)
- Alzheimer's (11)
- Biosimilars (33)
- Caught my eye (102)
- Cell and Gene (8)
- Chevron Deference (2)
- CMMI (29)
- Copay Accumulators (7)
- COVID (3)
- Drug Prices (58)
- Drug shortages (15)
- DTC (9)
- Employers (20)
- FDA (8)
- Generics (13)
- Health Equity (4)
- Healthcare Costs (41)
- Home Health (1)
- ICER (12)
- Importation (5)
- Inflation Reduction Act (69)
- Insulin (7)
- IP (3)
- Long term care (1)
- Medicaid (24)
- Medicare Advantage (27)
- Medicare Negotiation (68)
- Medicare Part D (78)
- Medicare Transaction Facilitator (5)
- Medicare Transaction Facilitator (12)
- Obesity (28)
- On the Horizon (1)
- Orphan Drugs (8)
- Pharmacy Benefit Managers (49)
- Preventative (5)
- Reference Pricing (26)
- State-based Reform (32)
- Supply Chain (8)
- Tariffs (2)
- Uncategorized (9)
- Utilization Management (14)
- Vaccines (10)
- Value (18)